EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer

Katherine E Lopez, Dawn M Meola, Nicholas D Camarda, Jenica N Upshaw, Iris Z Jaffe, Cheryl A London iD, Vicky K Yang iD

Journal of Veterinary Internal Medicine · 2025-05-01 · 39 (3)

DOI: 10.1111/jvim.70115 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, published online on 2025-05-01. Written by Katherine E Lopez and 6 co-authors. Institution: Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA. Major MEDLINE topics: Dog Diseases, Neoplasms, Vascular Endothelial Growth Factor A, Indoles. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, NIH HHS, American College of Veterinary Internal Medicine.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Hypertension is documented in dogs with cancer receiving toceranib, but no studies have evaluated left ventricular (LV) systolic function and biomarkers of endothelial function.

Objectives

To characterize changes in echocardiographic variables and biomarkers of endothelial function in dogs treated with toceranib. Animals Twenty-six client-owned dogs with no evidence of pre-existing cardiac disease or systemic hypertension are receiving a single agent toceranib for cancer treatment.

Methods

Dogs were enrolled in this prospective observational study with study visits at baseline, 1, 3, and 5 months after starting toceranib for echocardiographic exams, blood and urine collection, and blood pressure measurements, with an additional blood pressure obtained 2 weeks after starting toceranib. Serum markers of vascular endothelial function (VEGF, endothelin-1, platelet derived growth factor [PDGF], prostacyclin, cyclic guanosine monophosphate [cGMP]) and urinary nitrate were evaluated with ELISA.

Results

Dogs were enrolled between 2019 and 2023. Systolic blood pressure increased 2 weeks after initiating toceranib treatment (p = 0.009). Serum prostacyclin concentration was lower after 1 month of treatment (mean 98.8 pg/mL vs. 140.0 pg/mL at baseline, p = 0.03), and serum VEGF concentration was higher after 3 months of treatment (mean of 247.8 pg/mL vs. 135.4 pg/mL at baseline, p = 0.01). Global longitudinal strain (GLS) decreased at the five-month time point (mean −14.5% vs. −15.7% at baseline, p = 0.048) with no significant change in LV fractional shortening by M-mode or ejection fraction by Simpson's method of discs.

Conclusions

Dogs treated with toceranib might have higher systemic blood pressure associated with changes in VEGF and prostacyclin and decreased systolic function.

Subjects

MeSH terms (MEDLINE)

Dog DiseasesNeoplasmsVascular Endothelial Growth Factor AIndolesPyrrolesAntineoplastic AgentsEndothelium, VascularAnimalsDogsFemaleMaleBiomarkersEchocardiographyProspective StudiesBlood PressureHypertension

Author keywords

cardiotoxicityglobal longitudinal straintyrosine kinase inhibitorvasculotoxicity

Substances

Vascular Endothelial Growth Factor ABiomarkersIndolesPyrrolestoceranib phosphateAntineoplastic Agents

Authors and institutions

  • Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.
  • Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.
  • Tufts Graduate School of Biomedical Sciences, Boston, Massachusetts, USA.
  • Division of Cardiology, Tufts Medical Center, Boston, Massachusetts, USA.

ORCID profiles: Cheryl A London, Vicky K Yang

Funding

  • NCI NIH HHS
  • NIH HHS
  • American College of Veterinary Internal Medicine
  • NIGMS NIH HHS
  • Pacemaker Fund Grant
  • National Cancer Institute

Cite

APA

Lopez, K. E., Meola, D. M., Camarda, N. D., Upshaw, J. N., Jaffe, I. Z., London, C. A., & Yang, V. K. (2025). Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer. Journal of Veterinary Internal Medicine, 39(3). https://doi.org/10.1111/jvim.70115

Vancouver

Lopez KE, Meola DM, Camarda ND, Upshaw JN, Jaffe IZ, London CA, et al. Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer. Journal of Veterinary Internal Medicine. 2025;39(3). doi:10.1111/jvim.70115

BibTeX
@article{Lopez2025,
  author = {Lopez, Katherine E and Meola, Dawn M and Camarda, Nicholas D and Upshaw, Jenica N and Jaffe, Iris Z and London, Cheryl A and Yang, Vicky K},
  title = {Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  volume = {39},
  number = {3},
  doi = {10.1111/jvim.70115}
}
Start for free →